No on Prop. 14; no need to replicate California's disappointing stem cell experiment
By Editorial Board,
San Francisco Chronicle
| 09. 24. 2020
Like MySpace, the Martha Stewart prosecution and American democratic norms, spending gobs of state money on stem cell research might sound like an artifact of the Aughts. And yet 16 years after voters agreed to borrow $3 billion to explore a promising new area of medical research, stem cells are back on the California ballot.
The state’s voters passed Proposition 71, which created the California Institute for Regenerative Medicine, in a fit of hope that stem cells could treat an array of diseases and injuries. President George W. Bush’s order limiting federally funded embryonic stem cell research on religious grounds added urgency and politics to the cause. Celebrities such as Michael J. Fox and Christopher Reeve urged Californians to step into the breach for them and countless others with incurable, often heart-rending conditions.
Now the Oakland-based agency’s backers want voters to approve an additional $5.5 billion under Proposition 14 to sustain not just a limitless possibility but also the more mundane and complex reality of the institute’s experience. Especially in a field as nascent as stem cells, science is slow...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...